Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Delayed Data
As of Nov 25
 +0.13 / +0.07%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. It develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. Intercept Pharmaceuticals was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Contact Information

Intercept Pharmaceuticals, Inc.
450 West 15th Street
New York New York 10011
P:(646) 747-1000
Investor Relations:



Mutual fund holders53.75%
Individual stakeholders36.64%
Other institutional23.29%

Top Executives

Mark E. PruzanskiPresident, Chief Executive Officer & Director
Barbara Gayle DuncanChief Financial Officer, Secretary & Treasurer
David A. ShapiroChief Medical Officer & EVP-Development
Luciano AdoriniChief Scientific Officer
Rachel L. McMinnChief Strategy Officer